Table 2

Average response of the TLR-deficient EFs and WT-EFs to IgG purified from 6 patients with APS, 4 patients with autoimmune diseases, and from a pool of healthy controls

TLR1−/−EFTLR2−/−EFTLR4−/−EFTLR6−/−EFWT-EF
APLA 
    MCP-1 2.64 ± 0.87 1.16 ± 0.1* 27.85 ± 5.27 4.50 ± 2.33 16.02 ± 6.5 
    ICAM-1 2.95 ± 1.25 1.90 ± 0.24* 23.70 ± 7.25 3.55 ± 0.94 8.31 ± 2.02 
    IL-6 2.80 ± 0.74 1.70 ± 0.21* 23.90 ± 7.69 13.86 ± 7.9 18.35 ± 9 
AI IgG 
    MCP-1 0.81 ± 0.1 0.90 ± 0.16 1.58 ± 0.24 0.48 ± 0.6 1.0 ± 0.1 
    ICAM-1 1.04 ± 0.17 1.80 ± 0.36 2.66 ± 0.63 0.47 ± 0.18 1.81 ± 0.38 
    IL-6 0.84 ± 0.1 0.73 ± 0.13 1.57 ± 0.24 0.43 ± 0.19 1.10 ± 0.2 
Control IgG 
    MCP-1 0.85 ± 0.11 0.65 ± 0.14 1.12 ± 0.14 0.78 ± 0.22 1.15 ± 0.04 
    ICAM-1 0.90 ± 0.14 0.66 ± 0.27 1.03 ± 0.43 1.40 ± 0.4 1.15 ± 0.03 
    IL-6 1.23 ± 0.32 1.05 ± 0.45 1.28 ± 0.36 0.70 ± 0.28 1.55 ± 0.25 
TLR1−/−EFTLR2−/−EFTLR4−/−EFTLR6−/−EFWT-EF
APLA 
    MCP-1 2.64 ± 0.87 1.16 ± 0.1* 27.85 ± 5.27 4.50 ± 2.33 16.02 ± 6.5 
    ICAM-1 2.95 ± 1.25 1.90 ± 0.24* 23.70 ± 7.25 3.55 ± 0.94 8.31 ± 2.02 
    IL-6 2.80 ± 0.74 1.70 ± 0.21* 23.90 ± 7.69 13.86 ± 7.9 18.35 ± 9 
AI IgG 
    MCP-1 0.81 ± 0.1 0.90 ± 0.16 1.58 ± 0.24 0.48 ± 0.6 1.0 ± 0.1 
    ICAM-1 1.04 ± 0.17 1.80 ± 0.36 2.66 ± 0.63 0.47 ± 0.18 1.81 ± 0.38 
    IL-6 0.84 ± 0.1 0.73 ± 0.13 1.57 ± 0.24 0.43 ± 0.19 1.10 ± 0.2 
Control IgG 
    MCP-1 0.85 ± 0.11 0.65 ± 0.14 1.12 ± 0.14 0.78 ± 0.22 1.15 ± 0.04 
    ICAM-1 0.90 ± 0.14 0.66 ± 0.27 1.03 ± 0.43 1.40 ± 0.4 1.15 ± 0.03 
    IL-6 1.23 ± 0.32 1.05 ± 0.45 1.28 ± 0.36 0.70 ± 0.28 1.55 ± 0.25 

Data are expressed as the ratio (mean ± SE) of mRNA levels of the inflammatory marker proteins MCP-1, ICAM-1, and IL-6 in nonstimulated cells compared with IgG-stimulated cells.

AI indicates autoimmune.

*

Statistically different from WT-EFs and TLR4−/−EFs (P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal